Published

Tirzepatide

A dual GIP/GLP-1 receptor agonist and FDA-approved medicine (Mounjaro, Zepbound); like semaglutide, the live regulatory question is compounding, not approval.

Primary sources

Not staged

Evidence stage

Jul 2026

Last reviewed

What it is

Tirzepatide is a dual GIP/GLP-1 receptor agonist, marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea in adults with obesity).S1

Marketed as

As approved products, tirzepatide is marketed for type 2 diabetes and weight management; it is also widely promoted off-label and through compounders / telehealth for weight loss. The approved uses are evidence-backed (below); the compounded / off-label promotion is a separate marketing landscape.S1 S2

Regulatory status (US)

Tirzepatide is an FDA-approved drug — Mounjaro for glycemic control in type 2 diabetes and Zepbound for chronic weight management.S1 As with semaglutide, the live regulatory question is compounding: FDA has proposed to exclude tirzepatide (with semaglutide and liraglutide) from the 503B bulks list, and a final determination is pending.S2

Around the world

Tirzepatide is an approved medicine in multiple markets beyond the US under the Mounjaro and Zepbound brands.S1 As with other GLP-1-class products, the cross-border regulatory friction centers on compounded copies, not the approved drug.S2

Evidence

Tirzepatide has a robust randomized-trial base in its approved indications (the SURPASS diabetes program and SURMOUNT obesity program).S1 Efficacy statements should stay tied to the approved labeling and cited trials — not to compounded or off-label formulations.

Anti-doping

Tirzepatide is not currently prohibited in sport. From January 1, 2026, WADA placed markers of the incretin agonists (semaglutide and tirzepatide) on its Monitoring Program — surveillance, not a ban.S3 See the caveat on possible future changes.

⚑ Provisional

WADA is reported to be weighing whether to move GLP-1/GIP agonists from monitoring to prohibited status ahead of LA 2028; treat this as a possible future change, not current status. S3

Safety

As an approved drug, tirzepatide's safety is governed by its FDA labeling.S1 Separately, FDA has warned about unapproved or compounded GLP-1/GIP products marketed for weight loss — a distinct safety issue from the approved product.S2

What's changing

Two items to watch: FDA's final decision on the 503B bulks-list exclusion, and the WADA question flagged in the Anti-doping caveat.S2 S3

Sources

Every reference below is a primary source cited in this entry, drawn from the approved corpus.

01
FDA — FDA Approves New Medication for Chronic Weight Management (Zepbound/tirzepatide)
fda.gov · Federal regulatory statement
02
FDA — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
fda.gov · Federal regulatory statement
03
WADA — The Prohibited List (current International Standard)
wada-ama.org · Anti-doping standard

Follow this compound

Get an email when FDA / WADA / ClinicalTrials moves on Tirzepatide.

Follow this

The Panel Brief

What moved in supplement & peptide regulation this week. Free, cited, unsubscribe anytime.